Growth Metrics

Eli Lilly (LLY) FCF Payout Ratio Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Cover Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -18.69%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 20.26%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 9.35%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -49.49%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -16.50%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -10.25%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -67.11%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 56.25%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -18.69%
Dec 31, 2025 37.64%
Sep 30, 2025 -28.77%
Jun 30, 2025 -23.60%
Mar 31, 2025 175.99%
Dec 31, 2024 44.92%
Sep 30, 2024 -5.91%
Jun 30, 2024 63.72%
Mar 31, 2024 127.23%
Dec 31, 2023 -51.75%
Sep 30, 2023 20.60%
Jun 30, 2023 -301.75%
Mar 31, 2023 -43.85%
Dec 31, 2022 28.50%
Sep 30, 2022 5.39%
Jun 30, 2022 14.39%
Mar 31, 2022 -58.92%
Dec 31, 2021 -10.26%
Sep 30, 2021 24.39%
Jun 30, 2021 32.13%
Mar 31, 2021 -42.63%
Dec 31, 2020 5.30%
Sep 30, 2020 12.43%
Jun 30, 2020 -7.43%
Mar 31, 2020 19.09%
Dec 31, 2019 1.91%
Sep 30, 2019 7.90%
Jun 30, 2019 45.86%
Mar 31, 2019 82.79%
Dec 31, 2018 -14.86%
Sep 30, 2018 -21.25%
Jun 30, 2018 -13.64%
Mar 31, 2018 52.13%
Dec 31, 2017 -6.07%
Sep 30, 2017 -3.89%
Jun 30, 2017 -16.51%
Mar 31, 2017 -24.54%
Dec 31, 2016 -5.74%
Sep 30, 2016 7.29%
Jun 30, 2016 9.63%
Mar 31, 2016 -37.53%
Dec 31, 2015 24.11%
Sep 30, 2015 16.60%
Jun 30, 2015 15.09%
Mar 31, 2015 -65.82%
Dec 31, 2014 16.47%
Sep 30, 2014 9.72%
Jun 30, 2014 31.44%
Mar 31, 2014 145.24%
Dec 31, 2013 13.72%
Sep 30, 2013 -3.87%
Jun 30, 2013 5.16%
Mar 31, 2013 54.72%
Dec 31, 2012 14.54%
Sep 30, 2012 -5.56%
Jun 30, 2012 -12.21%
Mar 31, 2012 28.00%